Effects of probiotics on methionine cholinedeficient diet-induced steatohepatitis in rats

Turkish Journal of Gastroenterology

Volumn 23, Issue 2, 2012, Pages 110-121

  Karahan, Nermin ^a   Işler, Mehmet ^a   Koyu, Ahmet ^a   Karahan, Aynur G ^b   Başyiǧt Kiliç, Gülden ^c   Çiriş, Ibrahim Metin ^a   Sütçü, Recep ^a   Onaran, Ibrahim ^a   Çam, Hakan ^a   Keskin, Muharrem ^a  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b SULEYMAN DEMIREL UNIVERSITY   (Turkey)

^c Faculty of Agriculture ^*

Author keywords

Methionine choline deficient diet; Non alcoholic fatty liver disease; Probiotics

Indexed keywords

CASPASE 3; CASPASE 8; CHOLINE; METHIONINE; PROBIOTIC AGENT; PROTEIN BAX; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; ENTEROCOCCUS FAECIUM; ENZYME ACTIVITY; HISTOLOGY; HISTOPATHOLOGIC SKIN REACTION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LACTOBACILLUS FERMENTUM; LACTOBACILLUS PLANTARUM; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION; RAT; STEATOSIS; TREATMENT OUTCOME;

ALANINE TRANSAMINASE; ANIMALS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CASPASE 8; CHOLINE DEFICIENCY; DIET; DISEASE MODELS, ANIMAL; FATTY LIVER; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIVER; MALE; PROBIOTICS; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84861813773     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: 10.4318/tjg.2012.0330     Document Type: Article

References (55)

1. Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 2002; 16: 663-78.
2. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: 99-112.
3. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006; 40: 17-29.
4. Duvnjak M, Lerotic I, Barsic N, et al. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol 2007; 13: 4539-50. (Pubitemid 47455230)
5. Kojima H, Sakurai S, Uemura M, et al. Mitochondrial abnormality and oxidative stress in nonalcoholic steatohepatitis. Alcohol Clin Exp Res 2007; 31: 61-6.
6. Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol 2003; 38: 681-7. (Pubitemid 36560657)
7. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an under-recognized cause of cryptogenic cirrhosis. JAMA 2003; 11: 3000-4. (Pubitemid 37430103)
8. Shiffman ML. Anatomy and physiology of hepatic blood flow. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Diseases of the liver. Philadelphia: Lippincott Williams & Wilkins, 2002; 1186.
9. Farrell GC. Is bacterial ash the flash that ignites NASH? Gut 2001; 48: 148-9. (Pubitemid 32141833)
10. Thurman RG, Gao W, Connor HD, et al. Role of Kupffer cells in failure of fatty livers following liver transplantation and alcoholic liver injury. J Gastroenterol Hepatol 1995; 10: 24-30.
11. Nazim M, Stamp G, Hodgson HJ. Non-alcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth. Hepatogastroenterology 1989; 36: 349-51. (Pubitemid 19284541)
12. Wigg AJ, Roberts-Thomson IC, Dymock RB, et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48: 206-11. (Pubitemid 32141844)
13. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343-50. (Pubitemid 36152533)
14. Yang SQ, Lin HZ, Lane MD, et al. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A 1997; 94: 2557-62. (Pubitemid 27136914)
15. Sheth AA, Garcia-Tsao G. Probiotics and liver disease. J Clin Gastroenterol 2008; 42: 80-4.
16. Forsyth CB, Farhadi A, Jakate SM, et al. Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. Alcohol 2009; 43: 163-72.
17. Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003; 52: 988-97. (Pubitemid 36765291)
18. Caballero-Franco C, Keller K, De Simone C, Chadee K. The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol 2007; 292: 315-22.
19. Eizaguirre I, Urkia NG, Asensio AB, et al. Probiotic supplementation reduces the risk of bacterial translocation in experimental short bowel syndrome. J Pediatr Surg 2002; 37: 699-702. (Pubitemid 34517437)
20. Chiva M, Soriano G, Rochat I, et al. Effect of Lactobacillus johnsonii La1 and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis. J Hepatol 2002; 37: 456-62.
21. Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 2008; 49: 821-30.
22. Segawa S, Wakita Y, Hirata H, Watari J. Oral administration of heat-killed Lactobacillus brevis SBC8803 ameliorates alcoholic liver disease in ethanol-containing diet-fed C57BL/6N mice. Int J Food Microbiol 2008; 128: 371-7.
23. Velayudham A, Dolganiuc A, Ellis M, et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 2009; 49: 989-97.
24. Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology (Baltimore, Md) 2006; 44: 27-33. (Pubitemid 44049136)
25. www.nap.edu/catalog/5140.html.
26. Kiliç GB, Karahan AG. Identification of lactic acid bacteria isolated from the fecal samples of healthy humans and patients with dyspepsia, and determination of their pH, bile, and antibiotic tolerance properties. J Mol Microbiol Biotechnol 2010; 18: 220-9.
27. Aloǧlu H, Öner Z. Assimilation of cholesterol in broth, cream, and butter by probiotic bacteria. Eur J Lipid Technol 2006; 108i: 709-13. (Pubitemid 44475604)
28. Sundaram SS, Whitington PF, Green RM. Steatohepatitis develops rapidly in transgenic mice overexpressing Abcb11 and fed a methionine-choline-deficient diet. Am J Physiol Gastrointest Liver Physiol 2005; 288: 1321-7.
29. Diamant M, Blaak EE, de Vos WM. Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes? Obes Rev 2010; 10: 1-10.
30. Otte JM, Podolsky DK. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 2004; 286: 613-26.
31. Cabellero-Franco C, Keller K, De Simone C, Chadee K. The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol 2007; 292: 315-21.
32. Gotteland M, Cruchet S, Verbeke S. Effect of Lactobacillus ingestion on the gastrointestinal mucosal barrier alterations induced by indomethacin in humans. Aliment Pharmacol Ther 2001; 15: 11-7. (Pubitemid 32055581)
33. Yan F, Cao H, Cover TL, et al. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 2007; 132: 562-75. (Pubitemid 46274659)
34. Adawi D, Kasravi FB, Molin G, Jeppsson B. Effect of Lactobacillus supplementation with and without arginine on liver damage and bacterial translocation in an acute liver injury model in the rat. Hepatology 1997; 25: 642-7. (Pubitemid 27106447)
35. Ewaschuk J, Endersby R, Thiel D, et al. Probiotic bacteria prevent hepatic damage and maintain colonic barrier function in a mouse model of sepsis. Hepatology 2007; 46: 841-50. (Pubitemid 47436131)
36. Osman N, Adawi D, Ahrné S, et al. Endotoxin- and D-galactosamine-induced liver injury improved by the administration of Lactobacillus, Bifidobacterium and blueberry. Dig Liver Dis 2007; 39: 849-56. (Pubitemid 47215581)
37. Liu Q, Duan ZP, Ha DK. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004; 39: 1441-9. (Pubitemid 38569067)
38. Uysal KT, Wiesbrock SM, Hotamisligil GS. Functional analysis of tumor necrosis factor (TNF) receptors in TNF-alpha-mediated insulin resistance in genetic obesity. Endocrinology 1998; 139: 4832-8. (Pubitemid 28533428)
39. Diehl AM. Lessons from animal models of NASH. Hepatol Res 2005; 33: 138-44. (Pubitemid 41799792)
40. Kim JK, Kim YJ, Fillmore JJ, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001; 108: 437-46. (Pubitemid 32730790)
41. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001; 293: 1673-7. (Pubitemid 32807849)
42. Hirosumi J, Tuncman G, Chang L. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-6. (Pubitemid 35398190)
43. Esposito E, Iacono A, Bianco G, et al. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J Nutr 2009; 139: 905-11.
44. Vance JE, Vance DE. The role of phosphatidylcholine biosynthesis in the secretion of lipoproteins from hepatocytes. Can J Biochem Cell Biol 1985; 63: 870-81. (Pubitemid 16216555)
45. Rizki G, Arnaboldi L, Gabrielli B, et al. Mice fed a lipogenic methionine-choline-deficient diet develop hypermetabolism coincident with hepatic suppression of SCD-1. J Lipid Res 2006; 47: 2280-90. (Pubitemid 44936138)
46. Rinella ME, Elias MS, Smolak RR, et al. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine cholinedeficient diet. J Lipid Res 2008; 49: 1068-76.
47. Tahan V, Eren F, Yavuz D, et al. Rosiglitazone attenuates liver inflammation in a rat model of non-alcoholic steatohepatitis. J Hepatol 2003; 38: 202.
48. Müller AH, Grangette C, Goudercourt D, et al. Comparative cytokine inducing pattern of lactic acid bacteria used for mucosal vaccine development. Immunol Lett 1999; 69: 33.
49. Ibnou-Zekri N, Blum S, Schiffrin EJ, von der Weid T. Divergent patterns of colonization and immune response elicited from two intestinal Lactobacillus strains that display similar properties in vitro. Infect Immun 2003; 71: 428-36. (Pubitemid 36026047)
50. Gyamfi MA, Damjanov I, French S, Wan YJ. The pathogenesis of ethanol versus methionine and choline deficient diet- induced liver injury. Biochem Pharmacol 2008; 75: 981- 95.
51. Tait SW, Green DR. Caspase-independent cell death: leaving the set without the final cut. Oncogene 2008; 27: 6452- 61.
52. Canbay A, Higuchi H, Bronk SF, et al. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 2002; 123: 1323-30.
53. Martinon F, Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 2007; 14: 10-22. (Pubitemid 44911890)
54. Imeryuz N, Tahan V, Sonsuz A, et al. Iron preloading aggravates nutritional steatohepatitis in rats by increasing apoptotic cell death. J Hepatol 2007; 47: 851-9. (Pubitemid 350051114)
55. Anstee QM, Concas D, Kudo H, et al. Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J Hepatol 2010; 53: 542-50.